argenx SE
ARGX: XBRU (BEL)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|s$ | LOCK|z@^ | LOCK|$r%pJSD |
Argenx Earnings: Demand for Vyvgart Fuels Growth by Supporting Developing Pipeline
Argenx reported $949 million in second-quarter net product sales, with Vyvgart reaching over 15,000 patients globally across generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
